Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B
Eugene R. Schiff(University of Miami), Steven L. Chuck(Gilead Sciences (United States)), Norah A. Terrault(University of Southern California), Jean‐Pierre Villeneuve(Centre Hospitalier de l’Université de Montréal), Didier Samuel(Hôpital Paul-Brousse), Sarah Arterburn(Gilead Sciences (United States)), Ching‐Lung Lai(HKU-Pasteur Research Pole), P. Neuhaus(Charité - Universitätsmedizin Berlin), Stefan Zeuzem(Goethe University Frankfurt), Stephanos J. Hadziyannis(National and Kapodistrian University of Athens), Massimo Colombo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Carol Brosgart(Gilead Sciences (United States)), Hans L. Tillmann(Medizinische Hochschule Hannover), Katyna Borroto–Esoda(Gilead Sciences (United States))
Cited by 236
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION
|The Lancet|1989|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k